Rhenman & Partners Asset Management Ab Decreased Pfizer Inc (NYSE:PFE) Stake By $14.70 Million

October 13, 2017 - By Adrian Erickson

Investors sentiment decreased to 0.94 in Q2 2017. Its down 0.01, from 0.95 in 2017Q1. It dropped, as 58 investors sold PFE shares while 716 reduced holdings. 112 funds opened positions while 612 raised stakes. 4.02 billion shares or 1.07% less from 4.06 billion shares in 2017Q1 were reported. Gateway Advisory Limited Liability Company invested in 0.07% or 6,815 shares. Spinnaker Tru invested 0.26% in Pfizer Inc. (NYSE:PFE). Warren Averett Asset Mgmt Ltd Liability Com stated it has 0.26% of its portfolio in Pfizer Inc. (NYSE:PFE). Washington holds 0.65% in Pfizer Inc. (NYSE:PFE) or 315,650 shares. Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Invest Mngmt holds 687,400 shares. Moreover, Los Angeles Mngmt And Equity has 0.46% invested in Pfizer Inc. (NYSE:PFE) for 2.17M shares. Baxter Bros owns 0.25% invested in Pfizer Inc. (NYSE:PFE) for 24,747 shares. Sol Cap Mgmt owns 46,918 shares for 0.43% of their portfolio. Stock Yards Bankshares invested in 0.5% or 123,800 shares. Baldwin Brothers Ma owns 0.18% invested in Pfizer Inc. (NYSE:PFE) for 32,740 shares. Cambridge has 0.2% invested in Pfizer Inc. (NYSE:PFE). Kwmg Limited holds 47,164 shares. Rench Wealth Mgmt has 2.01% invested in Pfizer Inc. (NYSE:PFE) for 80,786 shares. Harvey Investment Ltd invested 0.28% in Pfizer Inc. (NYSE:PFE). S&Co Inc holds 28,787 shares or 0.13% of its portfolio.

Rhenman & Partners Asset Management Ab decreased its stake in Pfizer Inc (NYSE:PFE) by 97.58% based on its latest 2017Q3 regulatory filing with the SEC. Rhenman & Partners Asset Management Ab sold 420,000 shares as the company’s stock declined 3.45% while stock markets rallied. The institutional investor held 10,422 shares of the health care company at the end of 2017Q3, valued at $372,000, down from 430,422 at the end of the previous reported quarter. Rhenman & Partners Asset Management Ab who had been investing in Pfizer Inc for a number of months, seems to be less bullish one the $216.41 billion market cap company. The stock declined 0.08% or $0.03 reaching $36.31 per share. About 12.77M shares traded. Pfizer Inc. (NYSE:PFE) has declined 2.76% since October 14, 2016 and is downtrending. It has underperformed by 19.46% the S&P500.

Pfizer Inc. (NYSE:PFE) Ratings Coverage

Among 20 analysts covering Pfizer (NYSE:PFE), 8 have Buy rating, 1 Sell and 11 Hold. Therefore 40% are positive. Pfizer has $54.0 highest and $3300 lowest target. $38.63’s average target is 6.39% above currents $36.31 stock price. Pfizer had 59 analyst reports since July 29, 2015 according to SRatingsIntel. The stock of Pfizer Inc. (NYSE:PFE) has “Overweight” rating given on Friday, October 2 by Morgan Stanley. BMO Capital Markets maintained Pfizer Inc. (NYSE:PFE) on Tuesday, September 5 with “Buy” rating. As per Wednesday, November 25, the company rating was upgraded by SunTrust. The firm has “Hold” rating given on Friday, April 28 by BMO Capital Markets. Cowen & Co upgraded the shares of PFE in report on Tuesday, October 20 to “Outperform” rating. The company was maintained on Thursday, July 13 by Jefferies. Guggenheim initiated Pfizer Inc. (NYSE:PFE) on Friday, December 2 with “Neutral” rating. Argus Research maintained it with “Buy” rating and $41 target in Wednesday, July 29 report. On Thursday, September 14 the stock rating was maintained by Piper Jaffray with “Buy”. The rating was maintained by Jefferies with “Buy” on Thursday, August 4.

Pfizer Inc. is a research-based global biopharmaceutical company. The company has market cap of $216.41 billion. The Firm is engaged in the discovery, development and manufacture of healthcare products. It has a 26.47 P/E ratio. The Company’s global portfolio includes medicines and vaccines, as well as consumer healthcare products.

More notable recent Pfizer Inc. (NYSE:PFE) news were published by: Bloomberg.com which released: “Pfizer’s Big Deal Still Elusive as Company to Shed Consumer Unit” on October 10, 2017, also Seekingalpha.com with their article: “Recent Buy: Pfizer Inc.” published on September 14, 2017, Fool.com published: “Better Buy: Pfizer Inc. vs. Bristol-Myers Squibb” on September 17, 2017. More interesting news about Pfizer Inc. (NYSE:PFE) were released by: Seekingalpha.com and their article: “Pfizer: A Good Buy” published on October 02, 2017 as well as Barrons.com‘s news article titled: “Pfizer Seen Mulling Options” with publication date: October 12, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.